**Business Performance:** Neuland Labs delivered a strong Q2FY26, with total income soaring 63.7% year-over-year to Rs 516.1 Cr and profit (PAT) jumping 201.6% to Rs 96.5 Cr.

This stellar growth was primarily driven by commercial projects in its high-margin Custom Manufacturing Solutions (CMS) segment.

In the Generic Drug Substance (GDS) segment, Prime products like Ezetimibe were key drivers.

For the half-year (H1FY26), total income grew 7.5% to Rs 816.7 Cr, with PAT at Rs 110.2 Cr. **Growth Drivers & Strategy:** The company is strategically focusing on high-margin Specialty and CMS businesses, alongside enhancing its GDS offerings.

Investments are underway to capitalize on growth opportunities in both CDMO and generic APIs. **Recent Developments:** Unit-2 received a positive Establishment Inspection Report (EIR) following a US FDA inspection.

Neuland also filed one USDMF this quarter, and Unit-1 was honored with the 'Sword of Honour' for Health & Safety.

Net debt significantly improved to Rs (-6.6) Cr. **Key Financial Metrics:** Q2FY26 saw EBITDA surge 138.8% to Rs 156.9 Cr, with margins expanding to 30.4%. Earnings Per Share (EPS) for the quarter stood at Rs 75.2. **Management Commentary:** Management is optimistic, expecting the strong momentum from CMS commercial projects to continue.

They highlight the company's solid positioning to capture new opportunities and its strengthening reputation as a preferred partner.